Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Cash (2018 - 2025)

Historic Change in Cash for Autolus Therapeutics (AUTL) over the last 8 years, with Q3 2025 value amounting to -$37.7 million.

  • Autolus Therapeutics' Change in Cash rose 2212.42% to -$37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.9 million, marking a year-over-year decrease of 24212.87%. This contributed to the annual value of -$11.5 million for FY2024, which is 9190.46% up from last year.
  • Autolus Therapeutics' Change in Cash amounted to -$37.7 million in Q3 2025, which was up 2212.42% from $28.1 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Change in Cash high stood at $519.2 million for Q1 2024, and its period low was -$429.7 million during Q4 2024.
  • Over the past 5 years, Autolus Therapeutics' median Change in Cash value was -$39.4 million (recorded in 2023), while the average stood at -$3.5 million.
  • The largest annual percentage gain for Autolus Therapeutics' Change in Cash in the last 5 years was 141758.87% (2024), contrasted with its biggest fall of 250222.84% (2024).
  • Quarter analysis of 5 years shows Autolus Therapeutics' Change in Cash stood at $137.4 million in 2021, then surged by 59.67% to $219.4 million in 2022, then crashed by 107.53% to -$16.5 million in 2023, then plummeted by 2502.23% to -$429.7 million in 2024, then surged by 91.22% to -$37.7 million in 2025.
  • Its Change in Cash was -$37.7 million in Q3 2025, compared to $28.1 million in Q2 2025 and -$131.6 million in Q1 2025.